학술논문
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Document Type
article
Author
Jorge Labrador; David Martínez-Cuadrón; Adolfo de la Fuente; Rebeca Rodríguez-Veiga; Josefina Serrano; Mar Tormo; Eduardo Rodriguez-Arboli; Fernando Ramos; Teresa Bernal; María López-Pavía; Fernanda Trigo; María Pilar Martínez-Sánchez; Juan-Ignacio Rodríguez-Gutiérrez; Carlos Rodríguez-Medina; Cristina Gil; Daniel García Belmonte; Susana Vives; María-Ángeles Foncillas; Manuel Pérez-Encinas; Andrés Novo; Isabel Recio; Gabriela Rodríguez-Macías; Juan Miguel Bergua; Víctor Noriega; Esperanza Lavilla; Alicia Roldán-Pérez; Miguel A. Sanz; Pau Montesinos; on behalf of PETHEMA Group
Source
Cancers, Vol 14, Iss 9, p 2342 (2022)
Subject
Language
English
ISSN
2072-6694
Abstract
The hypomethylating agents, decitabine (DEC) and azacitidine (AZA), allowed more elderly acute myeloid leukemia (AML) patients to be treated. However, there are little direct comparative data on AZA and DEC. This multicenter retrospective study compared the outcomes of AZA and DEC in terms of response and overall survival (OS). Potential predictors associated with response and OS were also evaluated. A total of 626 AML patients were included (487 treated with AZA and 139 with DEC). Response rates were similar in both groups: CR was 18% with AZA vs. 23% with DEC (p = 0.20), CR/CRi was 20.5% vs. 25% (p = 0.27) and ORR was 32% vs. 39.5% (p = 0.12), respectively. Patients with leukocytes < 10 × 109/L, bone marrow blasts < 50% and ECOG ≥ 2 had higher ORR with DEC than with AZA. OS was similar in both groups: 10.4 months (95% CI: 9.2–11.7) vs. 8.8 months (95% CI: 6.7–11.0, p = 0.455), for AZA and DEC, respectively. Age (≥80 years), leukocytes (≥ 10 × 109/L), platelet count (9/L) and eGFR (≥45 mL/min/1.73 m2) were associated with higher OS with AZA compared to DEC. In conclusion, we found no differences in response and OS rates in AML patients treated with AZA or DEC.